Partners
Simon Fillatreau
ARTiDe project coordinator
S. Fillatreau is Professor of Immunology at the Medical Faculty of the University Paris Cité and AXA Professor in Translational Immunology. He is working at Institut Necker Enfants Malades (INEM), where he is leading the team “Immunity in Health and Disease” and is Director of the Department of Immunology, Infectiology, and Hematology. His research is devoted to the understanding of the mechanisms underpinning the pathophysiology of immune-mediated inflammatory diseases, and their physiological as well as therapeutic regulation with a current focus on regulatory T cells and regulatory B cells.
He is the coordinator of the project “Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes” (ARTiDe). This project will aim at characterizing disease-relevant autoreactive regulatory T cells (Tregs) in patients with type 1 diabetes (T1D) and, based on the acquired knowledge, develop an optimized cell therapy product consisting of T cell receptor (TCR)-engineered Tregs, which will be supported by the companion development of an automatized GMP-compliant process for the production of these genetically modified cells and the application for the regulatory authorizations needed to be in the position to launch a phase 1 clinical trial immediately at the end of the 5-years project.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
COORDINATOR
FRANCE
This French public scientific and technological institute is dedicated to biomedical research, human health, and involved in the entire range of activities from the laboratory to the patient’s bedside.
FRANCE
Founded by Marie Curie in 1909, Institut Curie is a leading cancer center with three missions: research, treament and transfer of knowledge. Its multi-disciplinary approach is part of the Institute’s bylaws.
POLAND
Clinical-stage company with advanced programmes focused on type 1 diabetes and other autoimmune diseases. Its mission is to develop effective T-regulatory cell (Treg) based therapies to improve the quality of life of patients and their families. Portfolio includes both polyclonal and engineered Treg products.
UNIVERSITÄTSKLINIKUM SCHLESWIG-HOLSTEIN
GERMANY
The University Hospital is one of the largest medical care centers in Europe. The unique feature of university medicine is the interaction of health care, research and teaching with the result that scientific findings flow directly into the health system.
FRANCE
This biotech company spin-off of renowned French public institutions possesses a deep expertise and extensive know-how in the field of data mining that supports drug development objectives.
GERMANY
This company provides a unique automated cell processing platform that enables GMP-compliant manufacturing of cell therapy products and has the clear mission to translate cellular therapies into clinical routine.
FRANCE
This tech transfer office, with over 20 years of EU project management, drives economic and social value across the translational continuum from fundamental and technological research to clinical and applied research.
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
FRANCE
This world-renowned university hospital center with a European dimension welcomes more than 10 million sick people each year thanks to its 38 hospitals. AP-HP offers all medical and surgical specialties and relies on all diagnostic and therapeutic possibilities.
Consortium
Industrial partners with key expertise involved in ARTiDe
The ambitious and innovative program of ARTiDe has been designed so that the overall goal, an antigen-specific Treg product ready for a phase I clinical trial available immediately at the end of the project, will be accomplished with high likelihood. This is possible because we build on the long-lasting experience and developments from our industrial partners, which have key expertise in genetically modified T cell manufacturing and GMP reagent production (MILTENYI) as well as clinical Treg manufacturing and Treg therapy in T1D (PolTREG). Together with the clinical departments associated with the project, they constitute the backbone of ARTiDe.
National and international previous and ongoing research and innovation activities feed into ARTiDe
All partners generated preliminary data, process and product developments that can now be brought to the next level by combining them in the + highly synergistic ARTiDe project aiming to translate them into clinical reality.
An inter-disciplinary approach
ARTiDe relies on a multidisciplinary approach integrating specialists in basic immunology and molecular biology, bioinformatics, medical immunology, T1D patient care, cell manufacturing, GMP process development and production, clinical trial design, regulatory affairs and ethical considerations. It is the strength of the consortium to integrate world-leading experts and commercial enterprises from these different fields, bringing the highly ambitious goal into reach.